Remedyvir's chief executive officer of Gilead Sciences, approved by the US Food and Drug Administration (FDA) as a treatment for Corona 19, said the drug will be administered to Corona 19 patients in the hospital within a few days. Will be.

"We are firmly focused on distributing this drug to the most critical patients across the country here," said Daniel O'Day Gilliard, CEO of US CBS broadcast program "Face The Nation." "We decide if the city is the most vulnerable and where the patients need it most, and we're going to give it to patients early next week."

Earlier, FDA chief Stephen Han announced on 1st that Gilead's Remdesivir has been approved for use in the treatment of Corona19 patients in hospital.

At the time, Vice President Mike Pence said he would pay for drugs starting April 4.

In a recent study led by the National Institutes of Health (NIH), Remdesivir has shown that some patients with Corona19 can shorten treatment times by as little as 4 days.

Remedyvir is administered via intravenous injection in a 5 or 10 day treatment course, depending on the patient.

O'Day says Gilead scientists are studying other routes of administration.

CEO O'Day said he has donated 1.5 million bottles in the initial supply.

This is a treatment for 100,000 to 200,000 people depending on the treatment period.

"We did so because we know the suffering and necessity of humanity," he said. "We want to make sure that there are no factors that will interfere with medication administration to patients."

The U.S. federal government plans to decide whether to set standards, such as a bed in an intensive care unit, or to see the path of infection in the United States, as to where to send Remdesibir.

"We will begin shipping tens of thousands of treatments early next week," Oday said. "Here, as the path of infection in the United States moves to several cities or regions, the federal government will adjust."

Remdesibir is known to be available in the United States and exported to other countries as a result of regulatory decisions.

O'Day said that Gilead is expecting more supplies of Remdesibir in the second half of 2020.

"We are working closely with the US government and governments around the world." I am adjusting it accordingly. ”